Preprint Altered herpesvirus-specific immune response is associated with long COVID, 2026, Joshi et al.

SNT Gatchaman

Senior Member (Voting Rights)
Staff member
Altered herpesvirus-specific immune response is associated with long COVID
Ruchika V Joshi; Rizwan Mr Khan; Katherine Jl Jackson; Sara Ballouz; Brendan Jacka; Leon Ni; Nicholas Findell-Aghnatios; Anupriya Aggarwal; Stuart G Turville; Manu Singh; Cynthia Yau; Ki Wook Kim; Anthony Byrne; Bruce J Brew; Gregory J Dore; David R Darley; Gail V Matthews; Anthony D Kelleher; Chansavath Phetsouphanh

Long COVID is associated with persistent immune dysregulation, but whether immunity to latent viruses is also altered remains unclear.

We profiled herpesvirus-specific antibodies and T-cell responses in people with long COVID and recovered convalescent controls at 4, 8, and 24 months after SAR-CoV-2 infection.

Overall antibody reactivity and abundance against cytomegalovirus (CMV) and Epstein-Barr virus (EBV) responder frequencies and circulating B-cell subsets were broadly preserved, but early antibody avidity and virus-specific CD4 T cell response magnitude were reduced. Neither virus nucleic acid was detected in plasma or stool at 4 or 8 months.

Here, we show that long COVID is associated with selective, time-dependent alteration of herpesvirus-specific immune memory, including relatively preserved or enhanced CD8 responses and greater representation of selected herpesvirus-associated T-cell receptor clonotypes.

Together, these findings indicate altered herpesvirus-specific antibody quality despite broadly preserved antibody abundance. Lower EBV avidity was associated with poorer quality of life and unrecovered status.

Web | DOI | PDF | Preprint: MedRxiv | Open Access
 
Lower CMV and EBV avidity despite broadly comparable IgG concentrations suggests that antibody quantity alone does not capture the altered humoral response in LC. Reduced avidity is consistent with differences in the maturation or maintenance of virus-specific antibody responses, but our data cannot determine whether this reflects altered germinal-centre selection, changes in memory B-cell recruitment, differences in antigen exposure, or a combination of these processes. Nor does lower avidity establish active herpesvirus replication, as we did not detect CMV or EBV nucleic acid in plasma or stool swabs.

Cellular findings point to a selective shift in the balance of virus-specific T-cell responses.

Circulating B-cell subset distributions were largely comparable, providing little evidence for broad B-cell compartment remodelling.

The clinical analyses suggest that lower early EBV avidity may mark a subgroup with poorer healthrelated quality of life and slower recovery. Lower-avidity LC participants had lower EQ-VAS at 4 and 8 months, while EQ-index was lower at 4 months; avidity also discriminated between recovered controls and unrecovered LC participants in exploratory ROC analyses.

Taken together, our findings support a model in which LC is associated with a persistent, but potentially partially reversible, distortion of herpesvirus-specific immune memory. This phenotype involves altered antibody quality and a modification in the magnitude and clonal representation of virus-specific T-cell responses, without evidence here of detectable CMV or EBV nucleic acid in plasma or stool.
 
Avidity = the overall binding strength of the antibody to its target antigen. cf affinity being the binding strength of just one of an antibody's binding sites to its target (single epitope). The immunologists can correct/refine this and the following comments.

So here, they're indicating that there's a shift in the quality of the antibodies to latent EBV, so each isn't quite as well matched. That could mean eg that immune complexes don't clear as quickly* as they ordinarily would and/or perhaps cause mischief in some yet-to-be-described manner, which results in long-term symptoms (ie "unrecovered") and poor quality of life secondary to those chronic symptoms. They don't show evidence of herpesvirus reactivation, so the shifted antibodies are presumably still maintaining adequate EBV etc immune surveillance.

But this is a hypothesis they're suggesting.

However, the avidity threshold was exploratory, the ROC analyses were conducted in the same cohort in which the association was observed, and the AUCs at 4 and 8 months did not differ significantly. The results therefore support further evaluation of EBV avidity as a candidate stratification measure, but do not establish a validated prognostic test or show that avidity itself drives persistent symptoms.

* my supposition, not in their discussion, but this week's other antibody paper did talk about immune-complex clearance. Antibody profiling in quantity and avidity across SARS-CoV-2 variants identifies distinct long Covid endotypes (2026)
 
Back
Top Bottom